SEM

SEM is now an event-driven situation more than a fundamentals story. On November 24, 2025, Executive Chairman and Co-Founder Robert Ortenzio made a non-binding indication of interest to take the company private for $16.00–$16.20 per share in cash, and a Special Committee is reviewing the proposal and other strategic alternatives. The stock at $16.53 already trades slightly ABOVE that indicated range, so the easy arbitrage is gone: downside reverts toward standalone value if the (non-binding, insider-conflicted) proposal is withdrawn, while upside requires the committee to negotiate a sweetened or competing bid. That asymmetry — capped upside, real deal-break risk — is what keeps this a hold rather than a buy despite a superficially cheap multiple.

The underlying business is healthier than the headline GAAP numbers suggest. Reported net income of $146M (-31.7%) and diluted EPS of $1.16 (-30.1%) are distorted by the November 2024 tax-free spin-off of Concentra, now reported as discontinued operations. On a continuing basis the MD&A reconciliation shows income from continuing operations net of tax rising from $129.987M (2024) to $214.533M (2025), operating income up 25.3% to $336M, and interest expense falling for a third straight year ($154.165M → $128.605M → $117.942M). Revenue grew 5.1% to $5.45B across 104 critical-illness hospitals, 38 rehab hospitals and 1,917 outpatient clinics. On continuing earnings the effective P/E is closer to ~10x, and P/S is just 0.4x — genuinely inexpensive for a business with improving operating profit.